Content note: This article is intended solely for healthcare professionals, pharmacy students and trainees, and organisational decision-makers. It is not intended for patients or members of the public and does not provide individual medical advice.
Introduction
What information must a pharmacist be able to find before dispensing a medicine product? The name and strength are only the beginning. Medicines need stricter packaging and labelling controls than ordinary consumer products – for good reason: A pack must allow healthcare professionals to identify the product, select it accurately, confirm its status and trace it through the supply chain. It must also provide clear information for appropriate use once the medicine leaves the pharmacy or hospital.
The statutory framework is set out mainly in the Human Medicines Regulations 2012. The Medicines and Healthcare products Regulatory Agency (MHRA) approves packaging and labelling information for medicines sold in the UK and publishes guidance on readability, pack design and patient information leaflets. Parallel-imported medicines are also subject to relevant packaging and labelling requirements, including requirements specific to UK Parallel Import Licences (PLPIs).
A major recent change is the “UK Only” statement. It forms part of the arrangements introduced under the Windsor Framework and has been required on new packs placed on the UK market since 1 January 2025.
In this article, we explain the main requirements, how they appear on medicine packs and why they matter. We also provide a practical checklist for healthcare professionals reviewing a pack for dispensing, procurement or stock control.
What information must appear on medicine packaging in the UK?
The main requirements are listed in Regulation 257 and Schedule 24 of the Human Medicines Regulations 2012. The information generally appears on both the outer packaging and the immediate packaging. Reduced particulars apply to blister packs enclosed in a compliant carton and to immediate packaging that is too small for the full text.
The information must normally be in English. Other languages may also appear if the same particulars are presented in each language. The wording must be easy to read, understandable and permanent.
The principal pack elements include:
- Medicine name: The authorised name of the medicinal product
- Strength and pharmaceutical form: For example, the amount of active substance and whether the medicine is supplied as tablets, capsules, solution or another form
- Intended age group: Where appropriate, the pack must state whether the product is intended for babies, children or adults
- Active substances: The pack must identify the active substances and state them quantitatively per dose unit, volume or weight, as applicable
- Pack contents: The quantity must be shown by weight, volume or number of doses
- Relevant excipients: All excipients must be listed for injectable, topical and eye preparations. Other products must declare excipients with a recognised action or effect, in line with applicable guidance
- Method and route of administration: The pack must explain how the medicine is administered and state the route where necessary
- Space for the prescribed dose: Must be provided where appropriate
- Child-safety warning: The packaging must state that the medicine should be kept out of the sight and reach of children
- Special warnings: Product-specific warnings must be included where required
- Expiry date: Must be stated clearly, normally by month and year
- Storage and disposal: Any special storage conditions and relevant disposal precautions must be shown
- Marketing authorisation holder: The name and address of the authorisation holder must
- appear, together with the representative where applicable.
- Marketing authorisation number: The relevant UK authorisation number must be included.
- Batch number: The manufacturer’s batch number supports product identification and
- Instructions for use: These are required on the packaging for products that are not
- prescription-only medicines.
- Legal category: Pharmacy medicines carry “P” in a rectangle. Prescription-only medicines carry “POM” in a rectangle.
- “UK Only”: This statement is required on applicable UK packs under the arrangements effective from 1 January 2025 (more information on this below)
A patient information leaflet must be included unless all required leaflet information appears on the outer or immediate packaging. The leaflet must be clear, legible and easy to use, and must reflect the approved product information.
Why medicine packaging and labelling matter
Medicine packaging is not simply a container for the product. In practice, it must help pharmacy and healthcare teams answer four immediate questions: What is this medicine? Is it the correct presentation? How should it be handled and supplied? Can it be traced if a problem arises?
Clear product identification
The pack must allow pharmacy and healthcare teams to verify the medicine name, strength, pharmaceutical form, pack size and route of administration. These details need to be easy to find and read. For example, the same medicine may be available in several strengths or as both tablets and an oral solution. If the distinguishing information is unclear, there is a greater risk of selecting the wrong presentation.
Reducing selection and dispensing errors
A pack should make it possible to distinguish one medicine from another, as well as one strength or formulation from another. This matters when products with similar names or similar-looking packs are stored near each other. Prominent placement of the medicine name, strength and pharmaceutical form helps the pharmacist make the correct selection before dispensing. Clear wording and visual hierarchy should guide the eye rather than make critical details compete for attention.
Supporting safe dispensing and medicine use
The pack provides practical information needed at different points in the supply process. A pharmacist may check the route of administration, storage conditions, expiry date and any special warnings before supply. The dispensing label then adds prescription-specific information, such as directions for use. For someone using the medicine at home, readable instructions and warnings help ensure that the information supplied by the pharmacy remains available after the medicine leaves the dispensary.
Supporting medicine traceability and recalls
The batch number, expiry date, marketing authorisation number and authorisation-holder details connect an individual pack to the regulated product and its supply history. If a quality defect, safety notice or recall affects a particular batch, these details help pharmacy, hospital and supply-chain teams identify the relevant stock rather than treating every pack as affected.
Accessibility supports all four functions. Legible print, a clear information hierarchy, Braille and access to suitable leaflet formats help ensure that essential information can be found and understood in professional settings and after supply.
Follow Abacus Medicine UK for insights on medicines, pharmacy and supply and company updates.
What does “UK Only” mean?
From 1 January 2025, all new packs of applicable licensed medicines placed on the UK market must display “UK Only”. This includes prescription-only medicines, pharmacy medicines and general sales list medicines. Stock released under the previous rules before 1 January 2025 may continue to be supplied in the relevant territory until expiry.
The requirement was introduced alongside the disapplication of EU Falsified Medicines Directive safety-feature requirements in Northern Ireland, completing the UK-wide change. “UK Only” identifies the intended market; it does not perform an authentication function.
Have you still seen anti-tamper packaging since January 2025 and wondered why? Older stock released before the rule change can remain in circulation, and the MHRA continues to encourage anti-tamper packaging, even though it is not mandatory. However, a 2D barcode containing an identifier uploaded to the European repositories system is prohibited on UK packs and, if present, must be fully removed or covered.
How “UK Only” applies to parallel-imported medicines
PLPI packs must also display “UK Only”. Unlike ordinary marketing-authorisation packs, PLPI products may continue to use approved stickering and over-labelling. The artwork must preserve the integrity of the primary packaging and must not obscure statutory text or original features needed for the safe and effective use of the medicine. For business context, see our overview of parallel import of medicines.
Is Braille required on medicine packaging?
Unless an exemption applies, the name of the medicinal product must be expressed in Braille on the outer packaging or, if there is no outer packaging, on the immediate packaging. The marketing authorisation holder must also make the package leaflet available on request in formats suitable for blind and partially sighted people.
The medicine name in Braille must not be abbreviated, according to the MHRA. It may appear on more than one side of the carton and may be placed over printed areas, provided the underlying text remains clear and visible.
Braille is one part of accessibility, but it is not a complete substitute for accessible product information: Clear print and access to suitable leaflet formats remain important for people with different levels of sight loss.
Checklist for pharmacy and procurement teams
When reviewing a medicine pack for dispensing, procurement or stock control, ask:
- Are the medicine name, strength and pharmaceutical form clear?
- Do the pack size and route of administration match the required presentation?
- Are the marketing authorisation and legal category shown where required?
- Are the batch number and expiry date legible?
- Are the storage instructions, disposal information and special warnings visible?
- Is Braille present and unobstructed where required?
- Is the current patient information leaflet included where required?
Does applicable stock placed on the UK market from 1 January 2025 display “UK Only”?
- Is any over-label permanent and approved, and does it leave critical information unobstructed?
- Is the dispensing label accurate, legible and positioned appropriately?
For parallel-imported stock, also ask:
- Does the UK presentation carry the correct PLPI details, and do the pack and leaflet correspond to the authorised presentation?
Key points
Clear medicine packaging and labelling support accurate identification, professional checks, traceability and appropriate use. The information must be visible, understandable and durable throughout the product’s shelf life.
This matters at every point in the supply chain. Pharmacists need immediate access to the product name, strength, form, batch, expiry, warnings and legal status. People using medicines at home need readable directions and access to the approved leaflet. Braille and alternative leaflet formats remain essential for blind and partially sighted people.
The “UK Only” statement is now a standard feature of applicable UK medicine packs placed on the market from 1 January 2025. Parallel-imported medicines are included, and their packaging, over-labelling, leaflet and Braille must meet applicable requirements before supply.
For parallel-imported medicines, Abacus Medicine prepares EEA-sourced original medicines for the UK market through authorised repackaging and labelling processes. Product-specific packaging and patient information leaflet artwork are subject to applicable MHRA requirements and regulatory processes before supply.
Discuss UK parallel-import medicine supply
Frequently Asked Questions (FAQ)
What information must appear on medicine packaging in the UK?
The required information includes the medicine name, strength, pharmaceutical form, active substances, contents, route, warnings, expiry date, storage conditions, authorisation holder, licence number and batch number. Other requirements apply according to the product, pack type and legal category.
Why do medicine packs say “UK Only”?
“UK Only” identifies a pack as intended for the UK market. The requirement took effect on 1 January 2025 under the Windsor Framework arrangements. The statement must appear clearly on the outer packaging in a font of at least 7 point.
How are parallel-imported medicines packaged for the UK market?
They may be professionally repackaged in a UK-specific replica pack or use approved over-labelling, depending on the authorised presentation. At Abacus Medicine, our first option is a replica pack with a new medicine carton, market-specific print and the required patient information leaflet. Only the presentation is adapted for the UK market; the imported medicine remains the original product, with its effectiveness, quality and pack size corresponding to the authorised UK reference product.
What are the UK requirements for a pharmacy dispensing label?
For a medicine supplied on prescription, the packaging must identify the individual where applicable, the name and address of the person who sells or supplies the medicine, and the date of supply. The medicine name, directions for use and precautions specified by the prescriber should also appear unless the pharmacist, exercising professional skill and judgement, considers one or more of those particulars inappropriate.
Sources and further reading
The following sources were used for this article and offer further reading for those interested in the topic.
- The Human Medicines Regulations 2012, Part 13: Packaging and leaflets. UK legislation, current revised version.
- The Human Medicines Regulations 2012, Schedule 24: Packaging information requirements. UK legislation, current revised version.
- Medicines: packaging, labelling and patient information leaflets. Medicines and Healthcare products Regulatory Agency, published 18 December 2014, updated 1 July 2026.
- Best practice in the labelling and packaging of medicines. Medicines and Healthcare products Regulatory Agency, published 29 December 2014, updated 3 July 2026.
- The Human Medicines Regulations 2012, Schedule 25: Packaging requirements, specific provisions. UK legislation, current revised version.
